Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement.

Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement

Amgen

CRISPR Therapeutics

Johnson & Johnson

Eli Lilly

Molina Healthcare

Merck

Novo Nordisk

Pfizer

Seagen

UnitedHealth Group

If you're looking for a sector that's on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.

Flee to Healthcare Stocks if Recession Rears its Head?

PepsiCo

Philip Morris

Rio Tinto plc Sponsored

Shell PLC

Stellantis N.V. 

Navigating the unpredictable waters of today's market, safe dividend stocks emerge as a beacon of reliability. Despite an optimistic kickoff this year, the broader market sentiment has chilled.

7 Safe and Steady Dividend Stocks to Buy for Volatile Time

Citigroup

Chevron

Target

TotalEnergies SE

Unilever

Looking for dividend stocks yielding 3% or more might seem pretty specific. Remember, though, the logic behind investing in underrated stocks is straightforward: Buy low and sell high in order to see a healthy return on your investment.

The Top 7 Underrated Dividend Stocks Yielding 3% or More

–All primary and secondary endpoints were met for second Phase 3 study (M21-310) and results were consistent with findings from first Phase 3 study (M21-309). – Results support onabotulinumtoxinA as a potential treatment option for moderate to severe platysma prominence.

Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX® Cosmetic) for the Treatment of Platysma Prominence

AstraZeneca

Currently, the S&P 500 and many sectors are outperforming the healthcare sector, presenting an opportunity to explore assets within this sector during the current period of apathy towards it. AstraZeneca's revenue was $11.42 billion in the second quarter of 2023, up 6% from the prior quarter and beating analysts' consensus estimates by $0.4 billion. At the same time, total sales of AbbVie products continue to decline year over year, amounting to about $13.87 billion for the three months ending June 30, 2023.

AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths

Abbott Labs

Abbott Laboratories and AbbVie used to be one and the same company. Both have raised their payouts for 51 years in a row, making them Dividend Kings.

2 Dividend Kings to Buy on the Dip and Hold Forever

Apple

Air Products and Chemicals

Caterpillar

Colgate-Palmolive

Clorox

General Dynamics

General Mills

Hormel Foods

Procter & Gamble

Starbucks

AT&T

AT&T 5.35 % Notes 2017-01.11.66 Global

Verizon

The market may move up and down irrationally and seemingly on a whim while our dividends remain much more stable, reliable, and predictable. Dividends may not increase every year and a cut or elimination is even possible but the odds are greatly reduced when you diversify among different companies and sectors and focus on dividend quality. It will be interesting to see how the market plays out in the last quarter of the year.

Dividend Income Update August 2023

AbbVie Inc. (NYSE:ABBV ) Morgan Stanley 21st Annual Global Healthcare Conference 2023 September 13, 2023 10:50 AM ET Company Participants Rob Michael - President, Chief Operating Officer Scott Reents - Chief Financial Officer Jeff Stewart - Chief Commercial Officer Roopal Thakkar - Head of Development, Regulatory Affairs. Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great.

AbbVie Inc. (ABBV) Management Presents at Morgan Stanley 21st Annual Global Healthcare Brokers Conference 2023 (Transcript)

The biotech sector is notorious for its sky-high R&D costs, regulatory hurdles, and lengthy timelines to bring a drug to market. Stock Strategist Andrew Rocco unveils 3 biotech stocks that have broken through and are set up for long term growth.

"Blockbuster Status": 3 Bios to Buy and Hold

AbbVie's (ABBV) Skyrizi met both primary endpoints of non-inferiority for clinical remission at week 24 and superiority of endoscopic remission at week 48 versus J&J's Stelara in a head-to-head study.

AbbVie's (ABBV) Skyrizi Crohn's Disease Study Meets Goals

Online and mobile voting is open to the public now through September 27 to help determine this year's two Thriving Students 40 students living with cystic fibrosis (CF) received $3,000 scholarships earlier this year based on their academic excellence, creativity, and community involvement Two deserving students will be awarded scholarships totaling $25,000 each NORTH CHICAGO, Ill. , Sept. 13, 2023 /PRNewswire/ -- AbbVie today announced the start of its two-week public voting period for the 2023 Thriving Undergraduate and Graduate Scholarships.

AbbVie Calls on Public to Vote for the 2023 AbbVie Cystic Fibrosis Scholarship "Thriving Students"

Bristol-Myers

Top-shelf dividend stocks tend to trade at hefty premiums. Amgen and Bristol Myers Squibb are two clear exceptions to this general rule of thumb.

2 Undervalued Dividend Stocks to Buy Now

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?

SEQUENCE, a Phase 3 head-to-head study (study drug open-label and efficacy assessment blinded) compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs1 Risankizumab met both primary endpoints of non-inferiority for clinical remission (Crohn's Disease Activity Index [CDAI]) at week 24 and superiority of endoscopic remission at week 48 versus ustekinumab All secondary endpoints achieved statistical significance for superiority versus ustekinumab Safety results were consistent with the overall safety profile of risankizumab, with no new safety risks identified NORTH CHICAGO, Ill. , Sept. 12, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced top-line results from the Phase 3 SEQUENCE clinical trial evaluating risankizumab (SKYRIZI®, 600 mg intravenous [IV] induction at week 0, 4 and 8 and 360 mg subcutaneous injection [SC] starting at week 12 and every 8 weeks thereafter) versus ustekinumab (STELARA®, IV dose at week 0 and 90 mg SC every 8 weeks thereafter) through week 48 in patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs.

AbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn's Disease

Cardinal Health

Gilead Sciences

Medtronic

The strong move higher that Nvidia has driven in the stock market this year has been significant, and the world of artificial intelligence has driven stock prices this year.

Big Institutions Grab ‘Strong Buy' Dividend Stocks in a Sector Not Totally Driven by AI

Accenture Plc

Automatic Data Processing

Applied Materials

ASML Hld

Best Buy

Blackrock Inc

Cisco Systems

Expeditors International of Washington

Fastenal

Ferguson Enterprises Inc

Garmin

Home Depot

Infosys

KLA-Tencor

Lockheed Martin

Lowe's

Lam Research

Mastercard

Monolithic Power Systems

Paychex

The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF, with a few minor twists. The portfolio fell by 0.57% in August, outperforming the S&P 500 by 1.02%. Year-to-date, the portfolio is up 14.07%. Since inception, the portfolio is generating 3.95% of alpha over the S&P 500.

4 Factor Dividend Growth Portfolio - Closing In On A Historic First Year

News for AbbVie Stock (ABBV)